Effective October 25, 2023, the following hypertension treatment medications have been added to the ADAP formulary: amlodipine, atenolol, carvedilol, diltiazem, enalapril, metoprolol succinate, metoprolol tartrate, nifedipine and olmesartan.
In the United States, nearly half of all adults have hypertension (or an elevated blood pressure). In addition, people with HIV over 50 years of age are 50 percent more likely to have hypertension than people of a similar age without HIV. Hypertension, when left untreated, may lead to cardiovascular disease (including heart attack), stroke, heart failure, and chronic kidney disease. Fortunately, hypertension can be treated with several classes of medication. Adequate access to hypertension treatment can prevent heart disease and related conditions and help people with HIV on antiretroviral therapy live longer, healthier lives. Adding hypertension medications amlodipine, atenolol, carvedilol, diltiazem, enalapril, metoprolol succinate, metoprolol tartrate, nifedipine and olmesartan to the ADAP formulary provides additional options to ensure that ADAP clients receive care consistent with current national guidelines.
ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of insulin and diabetes supplies.
If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov).
ADAP Branch Chief
California Department of Public Health